New research on safety of intracoronary delivery of adenovector reported in cover story of Molecular Therapy

ic genes in man at least using Collaterals intracoronary route of administration, said Jeffrey Friedman, M.D. vice president of development of Collateral Therapeutics. In particular, it provides important data which reinforces our prior views about the apparent safety of Collaterals proprietary approach of intracoronary delivery of genes to enhance angiogenesis as well as improve heart function. Furthermore, our unique approach allows delivery of genes at the time of cardiac catheterization without causing injury to the heart as in other techniques that require the heart to be punctured in order to deliver a therapeutic gene.

In the U.S., the adenoviral vector has been used in approximately one third of all gene therapy clinical trials, with adenovirus serotype 5 being the most widely used. These adenoviral vectors have now been used in investigational studies designed to evaluate the safety and efficacy of gene therapy in patients with cancer, cardiovascular disease and inherited disorders. According to the Office of Biotechnology Activities, National Institutes of Health, in the past decade, approximately 144 gene therapy clinical trials using adenoviral vectors have been conducted and of all patients who have participated in gene therapy trials, nearly 1 in 5 patients has been administered an adenoviral vector, said Christopher J. Reinhard president and chief operating officer of Collateral Therapeutics. Our lead product candidate, GENERX, uses the adenovirus serotype 5 to administer human growth factor, FGF-4, for the potential treatment of stable angina due to coronary artery disease. We are excited about these new studies, which further support the growing body of knowledge regarding the safety profile of adenoviral vectors for cardiovascular gene therapy, and we are pleased with the clinical progression of GENERX.

GENERX, a non-surgical angiogenic gene therapy, is being developed by Schering AG, Germany (NYSE: SHR) under an agreement wi

Contact: Lora Pike
Collateral Therapeutics

Page: 1 2 3

Related biology news :

1. Leader in cancer treatment and prevention research honored
2. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
3. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
4. Belgian researchers explore revolutionary approach to angiogenesis
5. Award winning researchers reveal potential new role for Glivec
6. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
7. 16 APS exercise research highlights, from reduced flu mortality to proteomics & obesity
8. Gene chips research in cotton could lead to superior variety
9. Groundbreaking research could ignite new solutions to heat transfer in nano-devices
10. New hydrothermal vents discovered as South Pacific Odyssey research begins
11. University of Alberta researcher looks for clues to mysterious disease

Post Your Comments:

(Date:11/9/2019)... , ... November 08, 2019 ... ... Pathology to form the leading provider of specialized histology, pathology, biomarker development, ... StageBio was recently created by the mergers of Histo-Scientific Research Laboratories (HSRL), ...
(Date:11/6/2019)... ARBOR, Mich. (PRWEB) , ... November 06, 2019 ... ... Mastermind® version 2.0 today. The Genomic Search Engine now includes the ... new functionality will further accelerate diagnosis of patients with genetic and rare diseases. ...
(Date:11/2/2019)... ... 01, 2019 , ... Stay on top of current hot topics through free ... all webinars is free, so be sure to register today to save your place! ... to see our upcoming webinars: , CLINICAL OPERATIONS , November 14 – Leveraging ...
Breaking Biology News(10 mins):
(Date:11/6/2019)... ... 06, 2019 , ... Diversified Technologies, Inc. has introduced a PEF ... hour to improve processing. , The DTI Industrial PEF Unit can pre-treat whole pieces ... juice yields by up to 50% and achieve up to an 80% reduction of ...
(Date:11/2/2019)... ... October 31, 2019 , ... A clinical trial ... each other: study managers, principal investigators, supply chain managers, manufacturers, IRT, CRAs and ... informed of the latest data, potentially leading to patient risk. , By having ...
(Date:10/29/2019)... Conn. (PRWEB) , ... October 28, 2019 , ... ... Advisory Board: , , Professor Jack R Wands, MD, of ... and Wyeth (Pfizer) , Professor Gil Mor, MD, PhD, of Wayne State ...
(Date:10/22/2019)... SOMERSET, N.J. (PRWEB) , ... October 22, 2019 , ... ... Director, Clinical Supply Services and Drug Product Technologies Integration, will participate in a panel ... Logistics Conference (HPCLC), to be held at the Gwen Hotel, Chicago, on Oct. 28-30, ...
Breaking Biology Technology:
Cached News: